Extended-release Guanfacine HCl (Intuniv, SPD503)
SPD503-318
Phase 3 small_molecule completed
Quick answer
Extended-release Guanfacine HCl (Intuniv, SPD503) for Attention Deficit Hyperactivity Disorder (ADHD) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention Deficit Hyperactivity Disorder (ADHD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed